Jeffrey T L Smith insider trades: Zymeworks (ZYME) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jeffrey reports to the SEC
Open-market buys and sales
32 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jan 12, 2026 | ZYME | ↓ Sell | 9,310 | $22.67 | $211K | Direct | Jan 12, 2026 (0d) |
| Jan 5, 2026 | ZYME | ↓ Sell | 10,538 | $25.10 | $264K | Direct | Jan 5, 2026 (0d) |
| Jan 6, 2025 | ZYME | ↓ Sell | 11,110 | $14.92 | $166K | Direct | Jan 6, 2025 (0d) |
| Sep 16, 2019 | ALDR | ↓ Sell10b5-1 | 32,728 | $18.44 | $604K | Direct | Sep 18, 2019 (2d) |
| Dec 3, 2018 | ALDR | ↓ Sell10b5-1 | 5,044 | $13.84 | $70K | Direct | Dec 4, 2018 (1d) |
| Nov 1, 2018 | ALDR | ↓ Sell10b5-1 | 5,040 | $13.42 | $68K | Direct | Nov 5, 2018 (4d) |
| Oct 1, 2018 | ALDR | ↓ Sell10b5-1 | 5,040 | $15.54 | $78K | Direct | Oct 3, 2018 (2d) |
| Sep 4, 2018 | ALDR | ↓ Sell10b5-1 | 5,040 | $18.00 | $91K | Direct | Sep 6, 2018 (2d) |
| Aug 1, 2018 | ALDR | ↓ Sell10b5-1 | 5,040 | $19.54 | $98K | Direct | Aug 2, 2018 (1d) |
| Jul 2, 2018 | ALDR | ↓ Sell10b5-1 | 12,161 | $15.49 | $188K | Direct | Jul 3, 2018 (1d) |
| Jun 1, 2018 | ALDR | ↓ Sell10b5-1 | 12,161 | $17.85 | $217K | Direct | Jun 5, 2018 (4d) |
| May 16, 2018 | ALDR | ↓ Sell10b5-1 | 12,161 | $15.03 | $183K | Direct | May 18, 2018 (2d) |
| Jun 20, 2017 | ALDR | ↓ Sell10b5-1 | 585 | $20.00 | $12K | Direct | Jun 22, 2017 (2d) |
| Dec 1, 2016 | ALDR | ↓ Sell10b5-1 | 3,000 | $22.78 | $68K | Direct | Dec 5, 2016 (4d) |
| Nov 1, 2016 | ALDR | ↓ Sell10b5-1 | 3,000 | $24.34 | $73K | Direct | Nov 3, 2016 (2d) |
| Oct 3, 2016 | ALDR | ↓ Sell10b5-1 | 3,000 | $31.14 | $93K | Direct | Oct 5, 2016 (2d) |
| Sep 1, 2016 | ALDR | ↓ Sell10b5-1 | 3,000 | $32.49 | $97K | Direct | Sep 6, 2016 (5d) |
| Aug 15, 2016 | ALDR | ↓ Sell | 3,000 | $31.17 | $94K | Direct | Aug 17, 2016 (2d) |
| Jun 3, 2016 | ALDR | ↓ Sell | 16,090 | $30.20 | $486K | Direct | Jun 7, 2016 (4d) |
| Dec 1, 2015 | ALDR | ↓ Sell10b5-1 | 4,272 | $37.24 | $159K | Direct | Dec 3, 2015 (2d) |
| Nov 2, 2015 | ALDR | ↓ Sell10b5-1 | 3,900 | $33.67 | $131K | Direct | Nov 4, 2015 (2d) |
| Oct 1, 2015 | ALDR | ↓ Sell10b5-1 | 3,900 | $32.25 | $126K | Direct | Oct 5, 2015 (4d) |
| Sep 1, 2015 | ALDR | ↓ Sell10b5-1 | 3,900 | $38.50 | $150K | Direct | Sep 3, 2015 (2d) |
| Aug 3, 2015 | ALDR | ↓ Sell10b5-1 | 3,900 | $45.64 | $178K | Direct | Aug 5, 2015 (2d) |
| Jul 1, 2015 | ALDR | ↓ Sell10b5-1 | 3,900 | $51.18 | $200K | Direct | Jul 6, 2015 (5d) |
| Jun 1, 2015 | ALDR | ↓ Sell10b5-1 | 3,900 | $41.53 | $162K | Direct | Jun 3, 2015 (2d) |
| May 22, 2015 | ALDR | ↓ Sell | 61,818 | $38.86 | $2.4M | Direct | May 26, 2015 (4d) |
| May 1, 2015 | ALDR | ↓ Sell10b5-1 | 3,900 | $25.67 | $100K | Direct | May 5, 2015 (4d) |
| Apr 1, 2015 | ALDR | ↓ Sell10b5-1 | 3,900 | $27.43 | $107K | Direct | Apr 3, 2015 (2d) |
| Mar 2, 2015 | ALDR | ↓ Sell10b5-1 | 3,900 | $26.25 | $102K | Direct | Mar 4, 2015 (2d) |
| Jan 27, 2015 | ALDR | ↓ Sell10b5-1 | 3,900 | $28.01 | $109K | Direct | Jan 28, 2015 (1d) |
| Nov 24, 2014 | ALDR | ↓ Sell | 29,090 | $16.08 | $468K | Direct | Nov 25, 2014 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other ZYME insiders
Open-market trades in the last 12 months
About Jeffrey T L Smith's insider trades
Jeffrey T L Smith is EVP & Chief Medical Officer at Zymeworks (ZYME). Since Nov 24, 2014, Jeffrey has reported no open-market purchases and 32 sales worth $7.6M on SEC Form 4. In the last 12 months: 2 sales ($476K).
25 sales (46% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Their filings also include option exercises (31 filings), grants and awards (12 filings), shares returned to the company (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every ZYME insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.